Posts for Ticker ‘REGN’

Top Day Trader Alerts (AIG, AONE, MBI, PALM, SIGM, REGN, CADX, TRA, CF, AGU, BRCD)

These are this morning’s top day trader and active trader alerts seen in the pre-market trading hours.  We also included some options color from yesterday.  A link has been provided for more detailed analysis and data for each stock over at VSInvestor.com:

American International Group, Inc. (NYSE: AIG) is down only about 2% after reports that the company could find itself leaderless again.

A123 Systems, Inc. (NASDAQ: AONE) is trading down 3% after earnings and concerns over a partnership.

MBIA Inc. (NYSE: MBI) is trading up over 3% this morning after getting crushed yesterday, M.J. Whitman’s Third Avenue took a stake.

Palm Inc. (NASDAQ: PALM) is running over 3% on an analyst call.

Sigma Designs, Inc. (NASDAQ: SIGM) is down 8% on a downgrade.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading up 10% after Sanofi-Aventis expanded its antibody pact substantially.

We have many options on watch as well:

  • Cadence Pharmaceutical Inc. (NASDAQ: CADX) is one to watch with a huge binary volatility trade ahead of the 11/13 PDUFA date for Acetavance as a treatment for acute pain.
  • There was some interesting options trading seen yesterday in the trifecta fertilizer merger war via Terra Industries Inc. (NYSE: TRA), CF Industries (NYSE: CF), and Agrium (NYSE: AGU).
  • Brocade Communications Systems, Inc. (NASDAQ: BRCD) gave a stock and option alert yesterday, but it went even more active in options with the NOV09 $9 CALLS seeing 24,450 contracts and the NOV09 $10 CALLS seeing 17,432 contracts.

You can join our open email distribution list which goes out several times per week to be notified of key merger news, key analyst calls, top early morning day trader alerts, along with news of IPO’s, key offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG

Posted on: November 11, 2009 – 9:09 am in Pre-Market Activity, Trading Alert, , , , , , , , , , ,

Top Analyst Upgrades (CHD, GPS, REGN, VOD)

The land of analyst upgrades and positive research calls from Wall Street looks pretty thin early this Monday morning:

Church & Dwight (CHD) Raised to Outperform at Oppenheimer.
Gap Inc. (GPS) Raised to Conviction Buy List at Goldman Sachs.
Regeneron (REGN) Raised to Buy at Piper Jaffray.
Vodafone (VOD) Raised to Buy at RBS.

JON C. OGG

Posted on: March 30, 2009 – 7:07 am in Analyst Calls, , , ,

Can Carl Icahn Fix Broken Biotechs? (ANX, BIIB, ENZN, IMCL, TELK, FOLD, AMLN, REGN)

Carl Icahn is a billionaire financier, activist, and investor.  Most think of Icahn as an activist investor that wants to get inside and drive value without having to acquire the whole company to resell it later.  This strategy works and works well, so long as the right strategies and efforts are applied properly to each stock.  The underlying sector a company is in is critical too, and for some reason Carl Icahn has been trying to do this in biotech stocks.  We took the biotech filings from both Mr. Icahn’s own holdings and from Icahn Capital LP to see what Mr. Icahn thinks he has up his sleeves.

CARL ICAHN direct holdings, via several investment vehicles:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $467,000.00 for 864,865 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $153.4M for 2,487,181 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $5.6M for 614,420 shares

ImClone Systems (NASDAQ: IMCL) down 18% from highs

  • $494.9M for 11,669,544 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $2.536M for 1,039,165 shares

ICAHN CAPITAL LP direct holdings:

Adventrx Pharmaceuticals Inc. (AMEX: ANX) down 80% from highs

  • $1.8M for 3,459,459 shares

Amicus Therapeutics, Inc. (NASDAQ: FOLD) down 45% from highs

  • $2.16M for 201,940 shares

Amylin Pharmaceuticals Inc. (AMLN) down 40% from highs

  • $185.1M for 6,339,653 shares

APPLERA (NYSE: ABI) down 10% from highs

  • $21.3M for 649,026 shares

Biogen-Idec (NASDAQ: BIIB) down about 25% from highs 

  • $613.7M for 9,948,723 shares

Enzon Pharmaceuticals (NASDAQ: ENZN) down only 16% from highs

  • $22.6M for 2,457,683 shares

Regenron Pharmaceuticals (NASDAQ: REGN) down about 28% from highs

  • $48.1M for 2,508,001 shares

Telik Inc. (NASDAQ: TELK) down over 50% from highs

  • $10.1M for 4,156,663 shares

*** percentage down from highs means the 52-week highs, so many are off much more than all-time or historical highs.

It may not be fair to refer to all of these as broken, because many aren’t.  What is interesting here is that if you follow biotech stocks and if you know these companies, most of these have fallen from their former glory.

Here is the problem with biotech stocks: They almost HAVE to be public to live up to expectations, so they very rarely go private because of the need for capital.  The mere nature of putting molecules and modified products into your body has risks, and many companies cannot control what happens or how people their meds after a while.  Biotech companies cannot control the FDA and they cannot control independent verification or investigative studies.  No company can control whether or not a competitor comes out with a greater product.  Biotechs are different in that investors would rather see a biotech spend cash to acquire another biotech rather than engage in a share buyback or pay out a dividend.  When was the last time you heard a broker or an investor discuss the high dividend check they expect from their biotech?  Me neither…

Mr. Icahn has a great track record of influencing companies.  He made a fortune off the move in Time Warner.  Motorola has so far been a flop and Yahoo! is just getting started.  But he didn’t become a billionaire by throwing darts nor by investing in mutual funds. 

But there is a real discourse here from biotechs to other sectors, and it would just seem much easier for Mr. Icahn to get better returns elsewhere.  It might be easier backing high-risk and high-reward biotech ventures from scratch instead of trying to fix existing biotechs with problems.

You can join our open email distribution list to hear about activist investing, special financings, M&A, IPO’s, secondary offerings, and other special situations.

Jon C. Ogg
May 16, 2008

Posted on: May 16, 2008 – 10:43 am in Biotech, , , , , , , ,

Biotech Business Daily (ANIK, ATHX, HALO, IDRA, MRK, OMPI, REGN, DDD, SQNM)

There are lots of names moving in biotech and related fields today, and below are some of the top movers:

Anika Therapeutics Inc. (NASDAQ: ANIK) moving up after reporting solid first quarter earnings this morning. The leader in tissue protection products and healing and repair based on hyaluronic acid (“HA”) technology showed double digit revenues in each product line for total revenue growth of 39%. Shares are up over 12% at $9.68. The 52-week range is $7.85 to $22.49.

Athersys, Inc. (NASDAQ: ATHX) dropping a whopping 23% today on no relevant news. Shares are down $0.70 to $2.30. The 52-week range is $1.55 to $10.00.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) up over 8% to $5.37. They announced that first quarter earnings will be released May 8 after market close and on May 9 they will provide a pipeline update. The 52-week range is $4.19 to $11.00.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today that under its collaboration agreement with Merck (NYSE: MRK), they achieved a preclinical milestone with a novel Toll-Like Receptor 9 agonists for an adjuvant in cancer vaccines. Idera should receive a milestone payment from Merck. Idera is up 3% to $14.34 off a 52-week range of $6.21 to $14.00. Merck is up over 1% to $38.77 on a 52-week range of $ 36.80 to $61.62. 

Obagi Medical Products, Inc. (NASDAQ: OMPI) is up over 7% to $8.62 on now news. The 52-week range for the skincare developer is $6.80 to $25.60.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) up 5% today after first quarter results were released this morning. They showed a loss of $11.6 million, or $0.15 EPS, narrower than the $29.9 million loss in first quarter 2007. Shares are up $1.11 to $20.73. The 52-week range is $13.55 to $28.74.

SCOLR Pharma Inc. (AMEX: DDD) up over 8% today after announcing that it entered into a lease buyout deal to move into a cheaper location, with the proceeds of over $4 million, the company said it will be able to fund 2009 expenses. Shares are trading at $1.26. The 52-week range is $0.13 to $4.07.

Sequenom Inc. (NASDAQ: SQNM) up today after reporting financial results after close yesterday. They posted a net loss of $8.6 million compared to a loss of $3.8 million in first quarter last year. Revenues increased by 7%. Shares are trading up over 8% to $6.85 on a 52-week range of $3.16 to $11.63.

Rachel Lopez
May 1, 2008

Posted on: May 1, 2008 – 1:58 pm in Biotech, , , , , , , , ,

Biotech Busine$$ Daily (ACAD, AMLN, CVTX, HALO, KOSN, MCU, NVAX, POZN, REGN, SIRT)

If you thought biotech news was getting quiet going into earnings season, think again.

Acadia Pharmaceuticals Inc. (ACAD) presents Phase II data on pimavanserin, a treatment  for Parkinson’s disease psychosis (PDP) at the 60th American Academy of Neurology Annual Meeting today. According the results from the study, pimavanserin is safe and effective at improving psychosis scores without hindering motor abilities. Shares are up $0.46 to $8.36 on a 52-week range of $7.63 to $17.33.

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up almost 3% in mid-morning trading. They announced that the earnings call is schedule for March 21. Trading at $30.42 on a 52-week range of $23.75 to $53.25.

CV Therapeutics, Inc. (NASDAQ: CVTX) soaring today after they announced Tuesday that they will receive $185 milliion from TPG-Axon Capital for rights to the sales of Lexiscan, a drug for patients that are unable to exercise during heart tests and was granted FDA approval last Thursday. Shares are up over 15% to $8.63 on a 52-week range of $5.41 to $13.74.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced pre-clinical findings in combinations of bisphosphonates and rHuPH20 at the American Association for Cancer Reseacrch conference today. The study showed that a combination of these molecules could reduce local irritation from chemotherapy by allowing a subcutaneous route of administration. Shares are up over 10% to $5.99 on a 52-week range of $4.19 to $11.00.

Kosan Biosciences Inc. (NASDAQ: KOSN) is still steadily rising after Monday announcement that Phase II testing for Epothilone KOS-1584 initiated. The drug targets patients with non-small cell lung cancer. Shares are up over 11% to $2.00 today. Monday, shares opened at $1.50. The 52-week range is $1.28 to $6.53.

Medicure Inc. (AMEX: MCU) up by 40% with the announcement that Phase II results for MC-1 and lisinpril for patients with type-II diabetes and hypertension will be presented at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference today. The data from the study was previously released. Shares are up 40% to $0.09 on a 52-week range of $0.05 to $1.64.

Novavax, Inc. (NASDAQ: NVAX) reported positive results in preclinical studies of Trivalent, a seasonal influenza vaccine. Phase II testing is hoped to begin in the third-quarter this year. Shares are up over 5% to $2.51. The 52-week range is $2.24 to $4.38.

Pozen, Inc. (NASDAQ: POZN) skyrocketing today on news that migraine drug Treximet has received FDA approval. They partnered with GlaxoSmithKline (GSK) for development of the drug. It is a follow up for Glaxo’s similar drug, Imitrex, which is set to lose patent protection in 2009. Pozen up 34% to $14.19 on a 52-week range of $8.29 to $19.75. Glaxo is up marginally to $42.57.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) moving higher than the rest today on no new developments. Shares are up $1.37 to $19.60 on a 52-week range of $13.55 to $28.74.

Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT) published a report by Scientific Advisory Board Co-Chairs that showed first in-vivo data demonstrating that SIRT1 enzymes suppress tumor development in colon cancer cells. Shares are up almost 5% to $12.56 on a 52-week range of $9.50 to $21.99.

Rachel Lopez
April 16, 2008

Posted on: April 16, 2008 – 11:18 am in Biotech, , , , , , , , , ,

Biotech Busine$$ Daily (AMLN, BIIB, CEPH, CYTK, ONXX, REGN, THRX, CBM)

Many biotech stocks are enjoying large gains Monday, although some are on no real breaking news. Here is a look at some notable gainers:

  • Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) up $1.39 to $28.97, a 5% increase. The 52-week range is $23.75 to $53.25.
  • Biogen Idec Inc. (NASDAQ: BIIB) up nearly $3.00, a 5% increase to $61.94. Carl Icahn on CNBC said today he is going to stay after the company.  The 52-week range is $43.43 to $84.75.
  • Cephalon Inc.  (NASDAQ: CEPH) up a modest 1% to $65.35. Last Thursday, they received FDA approval for Treanda, a treatment for chronic lymphocytic leukemia. The 52-week high is $84.83.
  • Cytokinetics, Incorporated (NASDAQ: CYTK) up over 2% to $3.49. Today the company announced positive results from Phase IIa trials of cardiac myosin activator drug CK-1827452 for patients with stable heart failure.
  • Onyx Pharmaceuticals (NASDAQ: ONXX) up $1.94 to $29.36, over 7% up. The 52-week range is $23.73 to $61.18
  • Regeneron Pharmaceuticals (NASDAQ: REGN) up $2.21 to $19.86, a 12% increase on the day. The 52-week range is $13.55 to $28.74
  • Theravance Inc. (NASDAQ: THRX) up $1.13 to $10.53, a 12% jump. The 52-week range is $9.37 to $36.98.

One biotech stock that isn’t enjoying the upswing is Cambrex Corp. (NYSE: CBM). The company hit a new low, down over 13% to $6.95 on news that UCB Groups Parkinson’s treatment, Neupro, is being recalled. Neupro uses their ingredient and the recall should impact earnings. First Analyis Sec downgraded the stock today.

Rachel Lopez
March 24, 2008

Posted on: March 24, 2008 – 2:00 pm in Biotech, , , , , , , ,

Icahn’s Top Holdings (APC, BEAS, BIIB, CSX, LEA, M, MOT, JCP, REGN, TIN, TWX, TWC, UNM, WMB)

Billionaire activist investor and financier Carl Icahn has released the total holdings in an SEC filing for the period end December 31, 2007 for  ICAHN CAPITAL, LP.

As Carl Icahn and his friends are multi-billionaires, we have eliminated the positions under $50 million since smaller postions are hardly worth his time and effort. The left column is the dollar amounts and the second number is the number of shares:

  • ANADARKO PETROLEUM (NYSE: APC) $970,600,000  14,775,468 shares
  • BEA SYSTEMS (NASDAQ: BEAS)  $654,176,000; 41,456,016 shares
  • BIOGEN IDEC (NASDAQ: BIIB)  $469,973,000; 8,256,723 shares
  • CSX CORP (NYSE: CSX) $128,422,000; 2,920,000
  • LEAR CORP (NYSE: LEA) 265,424,000; 9,595,954 shares
  • MACYS (NYSE: M)  $133,610,000; 5,164,660 shares
  • MOTOROLA (NYSE: MOT) $969,881,000; 60,466,400 shares
  • J.C.PENNEY (NYSE: JCP)  $183,274,000; 4,166,271 shares
  • REGENERON PHARMA (NASDAQ: REGN)  $60,568,000; 2,508,001 shares
  • TEMPLE INLAND (NYSE: TIN) $71,901,000; 3,448,488 shares
  • TIME WARNER CABLE (NYSE: TWC) $130,027,000; 4,711,128 shares
  • TIME WARNER INC (NYSE: TWX) $213,526,000; 12,933,159
  • UNUM GROUP (NYSE: UNM) $95,659,000; 4,020,960 shares
  • WILLIAMS COS INC (NYSE: WMB)  $173,201,000; 4,840,724 shares

Jon C. Ogg
February 14, 2008

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in any of the companies he covers.  Join the 24/7 Wall St. open email distribution list to hear of spin-offs, emerging IPO, break-up, reorganization, and other special situation stocks.

Posted on: February 14, 2008 – 11:58 am in Activist Investor, Insider Activity, Mutual Funds, , , , , , , , , , , , , , , ,

Biotechs & Pharmas Bracing For ASCO Annual Meeting

This weekend we have the mother of all future cancer treatment conferences: ASCO, or The American Society of Clinical Oncology.  Cancer stocks in the last few weeks have been seeing a muted response ahead of the event that biotech investors have traditionally braced for.  At various points on the website you can find a full list of contributing and presenting companies.  This is only a sample of the companies presenting data and it is very possible that the dates and even the companies may have changed.  Also, you’ll probably start seeing news here at this ASCO News Site either late Thursday evening or Friday. Some of these dates and presentation schedules have been compiled over a multi-week period, so it is very likely that some of these will have changed.

SATURDAY, JUNE 2

Genentech (DNA) will show data with Roche on Avastin plus a chemotherapy dual-mix cocktail for first line treatment in non-small cell lung cancer patients.  Later on at ASCO, a failed Avastin study for the treatment of pancreatic cancer will be shown.  Some Phase III Avastin data in kidney cancer will also be presented next week. Genentech will also be showing data with partners OSI Pharmaceuticals (OSIP) and Imclone (IMCL) in later days.

Pfizer (PFE) will present data on Sutent’s safety and efficacy in Phase II liver cancer studies.

If you forgot about Dendreon (DNDN), this will be the company’s last known data presentation on Provenge after getting the FDA delay.  Investors will be looking closely at any ‘New Data’ presented because much of the ongoing study data is being treated as old data.

Arqule (ARQL) and Exelixis (EXEL) are presenting data as well on molecules that are deemed cancer targets

Others to watch are Onyx Pharmaceuticals (ONXX) and partner Bayer (BAY), because their liver cancer studies are under concern over toxicity.  Its Nexavar data will be presented later for liver cancer Phase III.

Amgen (AMGN) will have study posters up discussing safety of its anemia treatment Aranesp that many patients have to use.  It is no secret that the reimbursement rates, effectiveness and safety, and the dosage have been under fire and worse for some time now.  Most of the damage has been done and many feel that more cautionary and worrisome days are ahead.

Immunogen (IMGN) will be releasing some preliminary data on Herceptin-DM1 in its Genentech pact for the treatment of breast cancer.

Read More »

Posted on: May 30, 2007 – 6:30 pm in Biotech, , , , , , , , , , , , , , , , , , , ,